Lenalidomide Enhances Antigen-Specific Activity and Decreases CD45RA Expression of T Cells from Patients with Multiple Myeloma

No abstract is available for this paper.

• Publication year

  2011

• Venue

  Journal of Immunology

• Publication date

  2011-07-15

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.4049/jimmunol.1002460PMID 21677134
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Dexamethasone synergizes with lenalidomide to inhibit multiple myeloma tumor growth, but reduces lenalidomide-induced immunomodulation of T and NK cell function.

  2010cited by this paper
• Lenalidomide as salvage therapy after allo-SCT for multiple myeloma is effective and leads to an increase of activated NK (NKp44+) and T (HLA-DR+) cells

  2010cited by this paper
• The anti-cancer agents lenalidomide and pomalidomide inhibit the proliferation and function of T regulatory cells

  2009cited by this paper
• Follicular lymphoma cells induce T-cell immunologic synapse dysfunction that can be repaired with lenalidomide: implications for the tumor microenvironment and immunotherapy.

  2009cited by this paper
• Immunomodulatory drugs reorganize cytoskeleton by modulating Rho GTPases.

  2009cited by this paper
• Melan-A/MART1 Analog Peptide Triggers Anti-myeloma T-cells Through Crossreactivity With HM1.24

  2009cited by this paper
• Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction

  2009cited by this paper
• Lenalidomide-induced upregulation of CD80 on tumor cells correlates with T-cell activation, the rapid onset of a cytokine release syndrome and leukemic cell clearance in chronic lymphocytic leukemia

  2009cited by this paper
• Lenalidomide alone or in combination with dexamethasone is highly effective in patients with relapsed multiple myeloma following allogeneic stem cell transplantation and increases the frequency of CD4+Foxp3+ T cells

  2009cited by this paper
• Eμ-TCL1 mice represent a model for immunotherapeutic reversal of chronic lymphocytic leukemia-induced T-cell dysfunction

  2009cited by this paper
• Lenalidomide Enhances Natural Killer Cell and Monocyte-Mediated Antibody-Dependent Cellular Cytotoxicity of Rituximab-Treated CD20+ Tumor Cells

  2008cited by this paper
• Chronic lymphocytic leukemia T cells show impaired immunological synapse formation that can be reversed with an immunomodulating drug.

  2008cited by this paper
• Thalidomide has both anti-inflammatory and regulatory effects in Behcet's disease

  2008cited by this paper
• Generation of Antitumor Invariant Natural Killer T Cell Lines in Multiple Myeloma and Promotion of Their Functions via Lenalidomide: A Strategy for Immunotherapy

  2008cited by this paper
• Immunomodulatory drugs Revlimid® (lenalidomide) and CC-4047 induce apoptosis of both hematological and solid tumor cells through NK cell activation

  2008cited by this paper
• Long-term Idiotype Vaccination Combined with Interleukin-12 (IL-12), or IL-12 and Granulocyte Macrophage Colony-Stimulating Factor, in Early-Stage Multiple Myeloma Patients

  2007cited by this paper
• Lenalidomide and CC-4047 inhibit the proliferation of malignant B cells while expanding normal CD34+ progenitor cells.

  2007cited by this paper
• Plasma cells from multiple myeloma patients express B7-H1 (PD-L1) and increase expression after stimulation with IFN-{gamma} and TLR ligands via a MyD88-, TRAF6-, and MEK-dependent pathway.

  2007cited by this paper
• Lenalidomide inhibits the malignant clone and up-regulates the SPARC gene mapping to the commonly deleted region in 5q− syndrome patients

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma.

  2007cited by this paper
• Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America.

  2007cited by this paper
• Phase I/II clinical trial of sequential subcutaneous and intravenous delivery of dendritic cell vaccination for refractory multiple myeloma using patient‐specific tumour idiotype protein or idiotype (VDJ)‐derived class I‐restricted peptides

  2007cited by this paper
• B7-1 and 4-1BB ligand expression on a myeloma cell line makes it possible to expand autologous tumor-specific cytotoxic T cells in vitro.

  2007cited by this paper
• Enhancement of ligand-dependent activation of human natural killer T cells by lenalidomide: therapeutic implications.

  2006cited by this paper
• Identification of a new HLA-A2-restricted T-cell epitope within HM1.24 as immunotherapy target for multiple myeloma.

  2006cited by this paper
• Cytotoxic T cells.

  2006cited by this paper
• Lenalidomide inhibits proliferation of Namalwa CSN.70 cells and interferes with Gab1 phosphorylation and adaptor protein complex assembly.

  2006cited by this paper
• Combined vaccination with idiotype-pulsed allogeneic dendritic cells and soluble protein idiotype for multiple myeloma patients relapsing after reduced-intensity conditioning allogeneic stem cell transplantation

  2006cited by this paper
• Lentiviral Transduction of Primary Myeloma Cells with CD80 and CD154 Generates Antimyeloma Effector T Cells

  2005cited by this paper
• Enrichment of functional CD8 memory T cells specific for MUC1 in bone marrow of patients with multiple myeloma.

  2005cited by this paper
• Combination therapy with lenalidomide plus dexamethasone (Rev/Dex) for newly diagnosed myeloma.

  2005cited by this paper
• Signalling molecules and cytokine production in T cells of multiple myeloma‐increased abnormalities with advancing stage

  2004cited by this paper
• Immunomodulatory drug costimulates T cells via the B7-CD28 pathway.

  2004cited by this paper
• Long-term follow-up of idiotype vaccination in human myeloma as a maintenance therapy after high-dose chemotherapy

  2004cited by this paper
• Idiotype vaccination in multiple myeloma induced a reduction of circulating clonal tumor B cells.

  2003cited by this paper
• Enhancement of Cytokine Production and AP-1 Transcriptional Activity in T Cells by Thalidomide-Related Immunomodulatory Drugs

  2003cited by this paper
• Thalidomide and a thalidomide analogue drug costimulate virus-specific CD8+ T cells in vitro.

  2003cited by this paper
• Degeneracy of Antigen Recognition as the Molecular Basis for the High Frequency of Naive A2/Melan-A Peptide Multimer+ CD8+ T Cells in Humans

  2002cited by this paper
• Dendritic cells are functionally defective in multiple myeloma: the role of interleukin-6.

  2002cited by this paper
• Apoptotic signaling induced by immunomodulatory thalidomide analogs in human multiple myeloma cells: therapeutic implications.

  2002influential reference
• Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma.

  2001cited by this paper
• Dendritic cells from patients with myeloma are numerically normal but functionally defective as they fail to up-regulate CD80 (B7-1) expression after huCD40LT stimulation because of inhibition by transforming growth factor-beta1 and interleukin-10.

  2001cited by this paper
• Extensive characterization of dendritic cells generated in serum-free conditions: regulation of soluble antigen uptake, apoptotic tumor cell phagocytosis, chemotaxis and T cell activation during maturation in vitro

  2000cited by this paper
• Vaccination of multiple myeloma patients with idiotype‐pulsed dendritic cells: immunological and clinical aspects

  2000cited by this paper
• Differential cytokine modulation and T cell activation by two distinct classes of thalidomide analogues that are potent inhibitors of TNF-alpha.

  1999influential reference
• High Frequencies of Naive Melan-a/Mart-1–Specific Cd8+ T Cells in a Large Proportion of Human Histocompatibility Leukocyte Antigen (Hla)-A2 Individuals

  1999cited by this paper
• Idiotype vaccination in human myeloma: generation of tumor-specific immune responses after high-dose chemotherapy.

  1999cited by this paper
• Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells.

  1999cited by this paper
• Clonal deletion of thymocytes as a tumor escape mechanism

  1998cited by this paper
• Graft-versus-myeloma effect: proof of principle.

  1996cited by this paper
• Clonal deletion of specific thymocytes by an immunoglobulin idiotype.

  1993cited by this paper
• A clinical staging system for multiple myeloma correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival

  1975cited by this paper
• Multiple myeloma.

  1948cited by this paper

• IKAROS regulates human T cell phenotype at a thymic and postthymic level

  2025cites this paper
• Myeloma cell intrinsic ANXA1 elevation and T cell dysfunction contribute to BCMA-negative relapse after CAR-T therapy.

  2025cites this paper
• Treatment of multiple myeloma: What is the impact on T-cell function?

  2024cites this paper
• Cytokines as Potential Therapeutic Targets and their Role in the Diagnosis and Prediction of Cancers.

  2023cites this paper
• Definition and Characterization of SOX11-Derived T Cell Epitopes towards Immunotherapy of Glioma

  2023cites this paper
• Lenalidomide improves NKG2D-based CAR-T cell activity against colorectal cancer cells invitro

  2023cites this paper
• Value of Cytokine Expression in Early Diagnosis and Prognosis of Tumor Metastasis

  2022cites this paper
• An Allogeneic Multiple Myeloma GM-CSF–Secreting Vaccine with Lenalidomide Induces Long-term Immunity and Durable Clinical Responses in Patients in Near Complete Remission

  2021cites this paper
• Molecular Mechanisms of Cereblon-Interacting Small Molecules in Multiple Myeloma Therapy

  2021cites this paper
• Cellular immunotherapy in multiple myeloma

  2019cites this paper
• IL-10 inducible CD8+ regulatory T-cells are enriched in patients with multiple myeloma and impact the generation of antigen-specific T-cells

  2018cites this paper
• Pilot trial of K562/GM-CSF whole-cell vaccination in MDS patients

  2018cites this paper
• The prognostic and predictive value of IKZF1 and IKZF3 expression in T-cells in patients with multiple myeloma

  2017cites this paper
• Immunotherapy for the treatment of multiple myeloma.

  2017cites this paper
• Immuno‐oncologic Approaches: CAR‐T Cells and Checkpoint Inhibitors

  2017cites this paper
• Defining the mechanisms by which lenalidomide can modulate the human T cell alloresponse to improve the outcome of allogeneic haematopoietic stem cell transplantation

  2017cites this paper
• Lenalidomide overcomes the immunosuppression of regulatory CD8+CD28− T-cells

  2017cites this paper
• Inhibition of lymphangiogenesis impairs antitumour effects of photodynamic therapy and checkpoint inhibitors in mice.

  2017cites this paper
• A phase I clinical study of autologous dendritic cell therapy in patients with relapsed or refractory multiple myeloma

  2017cites this paper
• Phase I–II study of lenalidomide and alemtuzumab in refractory chronic lymphocytic leukemia (CLL): effects on T cells and immune checkpoints

  2016cites this paper
• Myeloid-derived suppressor cells: The green light for myeloma immune escape.

  2016cites this paper
• Lenalidomide enhances myeloma-specific T-cell responses in vivo and in vitro

  2016cites this paper
• The immunotherapy era of myeloma: monoclonal antibodies, vaccines, and adoptive T-cell therapies.

  2016cites this paper
• A case of refractory multiple myeloma with proliferation of large granular lymphocytes by lenalidomide treatment and its association with clinical efficacy.

  2016cites this paper
• Versican vs versikine: tolerance vs attack.

  2016cites this paper
• Impact of lenalidomide on immune functions in the setting of maintenance therapy for multiple myeloma

  2015cites this paper
• Association of Antigen-Specific T-cell Responses with Antigen Expression and Immunoparalysis in Multiple Myeloma

  2015cites this paper
• Dendritic Cell-Based Cancer Immunotherapy against Multiple Myeloma: From Bench to Clinic

  2015cites this paper
• Lenalidomide consolidation and maintenance therapy after autologous stem cell transplant for multiple myeloma induces persistent changes in T-cell homeostasis

  2014cites this paper
• Targeted Therapy for HM1.24 (CD317) on Multiple Myeloma Cells

  2014cites this paper
• Treatment with lenalidomide induces immunoactivating and counter‐regulatory immunosuppressive changes in myeloma patients

  2014cites this paper
• Thalidomide maintenance therapy maturates the T cell compartment and compromises antigen-specific antitumor immunity in patients with multiple myeloma.

  2013cites this paper
• Potent in vitro and in vivo activity of an Fc-engineered humanized anti-HM1.24 antibody against multiple myeloma via augmented effector function.

  2012cites this paper
• Expansion of Polyfunctional HIV-Specific T Cells upon Stimulation with mRNA Electroporated Dendritic Cells in the Presence of Immunomodulatory Drugs

  2012cites this paper
• Presence of Immunomodulatory Drugs Electroporated Dendritic Cells in the Cells upon Stimulation with mRNA Expansion of Polyfunctional HIV-Specific T

  2012cites this paper
• Lenalidomide targets the T-cell co-stimulatory pathway to mediate immune modulation

  2012cites this paper
• Expansion of polyfunctional HIV-specific T cells upon stimulation with 1 mRNA electroporated dendritic cells in the presence of 2 immunomodulatory drugs 3 4 Short title : Effects of IMiDs on HIV-specific T cells 5 6 7

  2012cites this paper
• Lenalidomide enhances anti-myeloma cellular immunity

  2012cites this paper
• Regulation of Natural Killer Cells: SHIP-1, 2B4, and Immunomodulation by Lenalidomide

  2012cites this paper
• Molecular Action of Lenalidomide in Lymphocytes and Hematologic Malignancies

  2012cites this paper
• Reversal of T-cell Tolerance in Myelodysplastic Syndrome through Lenalidomide Immune Modulation

  2011cites this paper
• Association of Antigen-specific T-cell Responses with Antigen-expression and Immunoparalysis in Multiple Myeloma Statement of Translational Relevance

  year unknowncites this paper